Clinical trial
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic…
NCT00355238 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00355238 |
|---|---|
| Title | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer |
| Official title | A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma (HCC) |
| Intervention type | Drug |
| Interventions | brivanib (active) |
| Enrollment | 137 |
| Start date | Dec 31, 2006 |
| Primary completion | Apr 30, 2010 |
| Completion | Apr 30, 2010 |
| First posted | Jul 21, 2006 |
| Last update posted | Dec 1, 2023 |
| Countries | France, Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: